# Platelet aggregation and its modulation using antithrombotic agents

## TL;DR

This study evaluates how three antithrombotic agents affect platelet aggregation, finding that one agent is particularly effective.

## Contribution

The study introduces three new antithrombotic agents and identifies one with strong platelet aggregation inhibition.

## Key findings

- AV-303 showed the strongest dose-dependent inhibition of platelet aggregation.
- All three agents inhibited platelet aggregation compared to controls (p < 0.05).
- The findings suggest potential medical applications for treating thrombotic disorders.

## Abstract

Aggregation of platelets using three antithrombotic agents such as Ticagrelor Derivative (TD-101), Rivaroxaban Analog (RA-202) and
Apixaban Variant (AV-303) were assessed. All the three agents showed dose-dependent inhibitory effects in platelet aggregation where
AV-303 exhibited the strongest inhibitory activity according to light transmission aggregometry. The statistical analysis showed
distinctions (p < 0.05) between groups receiving treatment and controls. This opens possibilities for medical applications in
thrombotic disorder treatment. It should be noted that additional animal tests and clinical studies are needed to validate effectiveness
and safety of these agents.